Jim Trenkle
Directeur/Bestuurslid bij Veralox Therapeutics, Inc.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Peter C. M. McWilliams | M | - |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
Matthew B. Boxer | M | - |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 7 jaar |
Steven Jon Axon | M | 49 |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
Kasim Kutay | M | 59 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 8 jaar |
David J. Maloney | M | - |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 7 jaar |
Lars Rebien Sørensen | M | 69 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 7 jaar |
Christopher Starr | M | 71 |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | 8 jaar |
Viviane Monges | F | 60 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 6 jaar |
Britt Meelby Jensen | F | 51 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 2 jaar |
Max Løwe | M | - |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 19 jaar |
Selim Aissi | M | 60 |
Haas School of Business
| 9 jaar |
Carlos Solorzano | M | - |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | 5 jaar |
Carda Alba Zurriaga | M | - |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | 2 jaar |
Benjamin Scruggs | M | - |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 3 jaar |
Yury Kukushkin | M | - |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 4 jaar |
Ming Cheah | M | - |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | 4 jaar |
Ken Harrison | M | - |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
Gary D. Hammer | M | - |
University of Michigan
| 25 jaar |
megan krench | M | - |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | 3 jaar |
Kenneth Harrison | M | 44 |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
Cris de Luca | M | - |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | 4 jaar |
Ranjana Clark | F | 63 |
Haas School of Business
| 8 jaar |
Nigel Govett | M | 50 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 2 jaar |
Paulina Hill | M | 42 |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | 2 jaar |
Alex Martin Martin | M | 55 |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 4 jaar |
Francis Cuss | M | 70 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 7 jaar |
Constance Moore | F | 68 |
Haas School of Business
| 9 jaar |
Abhijeet Lele | M | 58 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 4 jaar |
Jamie Stiff | M | - |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | - |
Allen S. Lichter | M | 77 |
University of Michigan
| 26 jaar |
Jonathan Mow | M | 59 |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 1 jaar |
Thomas Dyrberg | M | 69 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 24 jaar |
Emmanuelle Coutanceau | M | 44 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 6 jaar |
Peter Young | M | 74 |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 1 jaar |
Daniel Mahony | M | - |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | - |
Thomas N. Gladwin | M | 74 |
University of Michigan
| 26 jaar |
Niall O'Donnell | M | 51 |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
Susanne Antonie Schaffert | M | 57 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | - |
Søren Møller | M | 56 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 13 jaar |
Marcus Remmers | M | - |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Marc Weiser | M | - |
University of Michigan
| 9 jaar |
Jeneanne Hanley | F | 51 |
University of Michigan
| 10 jaar |
Stephanie Cuttler Aument | F | - |
University of Michigan
| 2 jaar |
Dawn Parsons | F | - |
University of Michigan
| 12 jaar |
Robert G. Wilson | M | - |
University of Michigan
| 2 jaar |
Brian Scott Stutland | M | 49 |
University of Michigan
| 6 jaar |
Adil Haque | M | - |
University of Michigan
| 4 jaar |
Walter Joseph Liu | M | 45 |
University of Michigan
| 5 jaar |
Martin Valdes | M | - |
University of Michigan
| 2 jaar |
Keenan Kwok | M | - |
University of Michigan
| 5 jaar |
Todd Halonen | M | - |
University of Michigan
| 9 jaar |
David M. Flannery | M | - |
University of Michigan
| 5 jaar |
Valerie Chase | F | 41 |
University of Michigan
| 5 jaar |
Oliver Yucheng Chen | M | 45 |
University of Michigan
| - |
Daniel Mansuri | M | - |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | 3 jaar |
Jeremy Schneider | M | - |
University of Michigan
| 4 jaar |
Nathan Pacer | M | - |
University of Michigan
| 4 jaar |
Mark LaRosa | M | - |
University of Michigan
| 6 jaar |
Dave Repp | M | - |
University of Michigan
| - |
Seksan Kiatsupaibul | M | 51 |
University of Michigan
| 5 jaar |
Vicky Vergilius Gunawan | M | 41 |
University of Michigan
| 6 jaar |
Mark A. Borsos | M | - |
University of Michigan
| 7 jaar |
Kuan Hsu | M | - |
University of Michigan
| 6 jaar |
Becky A. Navin | F | - |
University of Michigan
| 3 jaar |
Atiba T. Edwards | M | - |
University of Michigan
| 6 jaar |
Jason B. Koenig | M | - |
University of Michigan
| 7 jaar |
Dave J. Hiemstra | M | - |
University of Michigan
| 2 jaar |
James Bunn | M | 51 |
University of Michigan
| 4 jaar |
Adam P. Wise | M | - |
University of Michigan
| 5 jaar |
Annie Maxwell | F | - |
University of Michigan
| 5 jaar |
Jeffrey Thomas Prince | M | - |
University of Michigan
| 15 jaar |
Chetan Jain | M | - |
University of Michigan
| 3 jaar |
Steven Scott Rodriguez | M | - |
University of Michigan
| 5 jaar |
J. Webster Stayman | M | - |
University of Michigan
| 5 jaar |
Tonya Bakritzes | F | - |
University of Michigan
| 5 jaar |
Elizabeth Maclin | F | - |
University of Michigan
| 2 jaar |
Jason Park | M | 47 |
University of Michigan
| 5 jaar |
Marc L. Walinsky | M | - |
University of Michigan
| 5 jaar |
Michael W. Vostrizansky | M | - |
University of Michigan
| 5 jaar |
Ben Lewis | M | 43 |
University of Michigan
| 7 jaar |
Daniel Quigley | M | - |
University of Michigan
| 7 jaar |
Michelle Sweet | F | - |
University of Michigan
| 4 jaar |
Bethany Steinhaus | F | - |
University of Michigan
| 4 jaar |
Andrew Bratt | M | - |
University of Michigan
| 9 jaar |
Eric Smith | M | - |
University of Michigan
| 4 jaar |
Fintan Walton | M | - |
University of Michigan
| 1 jaar |
Timothy Goldberg | M | - |
University of Michigan
| 4 jaar |
Emily Azevedo | F | - |
University of Michigan
| 4 jaar |
David Moehring | M | - |
University of Michigan
| 6 jaar |
Zoltan Gombosi | M | - |
University of Michigan
| 2 jaar |
Colleen Hoy | F | - |
University of Michigan
| 3 jaar |
Angelo Perez | M | - |
University of Michigan
| 5 jaar |
Brad Hanan | M | - |
University of Michigan
| 4 jaar |
Iman Adiwibowo | M | - |
University of Michigan
| 3 jaar |
Jason Townsend | M | - |
University of Michigan
| 5 jaar |
Alter Michelle Jessica | F | - |
University of Michigan
| 4 jaar |
Jason Glasser | M | - |
University of Michigan
| 3 jaar |
Werlson Hwang | M | - |
University of Michigan
| 4 jaar |
Steven Rosenblatt | M | - |
University of Michigan
| 4 jaar |
Katharine Melzer | F | - |
University of Michigan
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 86 | 86.00% |
Denemarken | 14 | 14.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Jim Trenkle
- Persoonlijk netwerk